ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CONSUMERS USING GLP-1 MEDICATIONS FOR WEIGHT LOSS SKEW YOUNGER AND HIGHER INCOME, NUMERATOR REPORTS

CHICAGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Numerator, a data and tech company serving the market research space, is reporting new information on the demographics of consumer households using GLP-1 medications. The Numerator analysis provides detailed information based on a survey and purchase behavior of over 100,000 panelists on their usage of GLP-1 medications for diabetes management and weight loss. Numerator has further segmented results based on the respondents’ intent to lose more or less than 15 pounds.

“Brands and retailers designing strategies to compete in a GLP-1 environment need to start with understanding who consumers are and what they’re trying to accomplish. People using the medication to manage chronic medical conditions like diabetes and obesity behave differently than those using the medication to lose smaller amounts of weight,” said Eric Belcher, CEO, Numerator. “The depth of Numerator’s panel – the larger panel size, stricter qualification requirements, and higher trip coverage – allows us to segment results based on weight loss goals and leverage years of consumer profile collections to understand how consumers feel about and manage their health.”

Numerator collects data on usage across a range of demographics as well as across thousands of descriptors that panelists have assigned to themselves over time, for example, the degree to which they actively manage their health and are concerned about what they eat.

Numerator researchers expect consumer profiles to evolve over time as the medications become more mainstream and more people gain familiarity with them. Numerator data already shows that consumers are increasingly using GLP-1 medications for weight loss management. Only 10% of GLP-1 users in October 2022 and prior reported using the medication for weight loss exclusively. This number has increased to 43% in July-October 2023.

Demographic findings include: 

  • Consumers using GLP-1 medications for weight loss skew younger and higher income. 
    • 71% of respondents using the medication for weight loss are Gen X or Millennials, with just 24% being Boomers. 
    • Among those using the medication for diabetes management, 39% are Gen X or Millennials while 60% are Boomers. 
    • Gen Z are 5x more likely than other generations to report they are using the medication for weight management vs. diabetes management.
  • Consumers using GLP-1 medications for less than 15 pounds of weight loss skew younger still.  
    • 42% of respondents using the medication for <15 pounds of weight loss are Millennials or Gen Z, up from 28% of those using the medication for >15 pound weight loss.
  • Consumers using the medication for weight loss are twice as likely to be high income than those using the medication for diabetes management. 
  • 67% of consumers using the medication to lose <15 pounds already actively manage their health versus 51% of people using the medication to lose >15 pounds.
  • There are no major differences in the household size of consumers using the medication for diabetes or any degree of weight loss.

 

GLP-1 Usage/Reason for Usage by Selected Demographics

  Never Used Diabetes Weight Loss Weight Loss >15 lbs Weight Loss <15 lbs
GENERATION          
Boomers 42% 60% 24% 26% 20%
Gen X 30% 32% 44% 47% 38%
Millennials 30% 7% 27% 24% 35%
Gen Z 5% 1% 5% 4% 7%
INCOME LEVEL          
High Income (>$125k) 29% 21% 39% 41% 34%
Middle Income ($40k - $125k) 48% 50% 39% 42% 32%
Low Income (< $40k) 24% 29% 22% 17% 35%
ACTIVELY MANAGE THEIR HEALTH          
Very Active 21% 24% 31% 23% 47%
Active 32% 29% 26% 28% 20%
Somewhat Active 32% 31% 27% 32% 17%
Slightly Active 11% 11% 9% 11% 5%
Not at all Active 5% 5% 7% 6% 10%
HOUSEHOLD SIZE          
1 26% 27% 23% 21% 28%
2 39% 42% 34% 36% 28%
3 15% 15% 17% 18% 17%
4+ 20% 17% 26% 25% 27%

 

Next Up:  Numerator reporting on shifts in consumer behavior related to GLP-1 usage.

About Numerator:                                                                                                    

Numerator is a data and tech company bringing speed and scale to market research.  Numerator blends first-party data from over 1 million US households with advanced technology to provide 360-degree consumer understanding for the market research industry that has been slow to change. Headquartered in Chicago, IL, Numerator has 2,000 employees worldwide; 80 of the top 100 CPG brands’ manufacturers are Numerator clients.


Bob Richter
Numerator
212-802-8588
press@numerator.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.